Equities

Veracyte Inc

Veracyte Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)33.76
  • Today's Change-0.56 / -1.63%
  • Shares traded1.11m
  • 1 Year change+38.76%
  • Beta1.6534
Data delayed at least 15 minutes, as of Sep 18 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.

  • Revenue in USD (TTM)399.58m
  • Net income in USD-54.04m
  • Incorporated2006
  • Employees815.00
  • Location
    Veracyte Inc6000 Shoreline Court, Suite 300SOUTH SAN FRANCISCO 94080United StatesUSA
  • Phone+1 (650) 243-6300
  • Fax+1 (650) 243-6301
  • Websitehttps://www.veracyte.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
VCYT:NMQ since
announced
Transaction
value
C2i Genomics IncDeal completed08 Jan 202408 Jan 2024Deal completed31.21%95.00m
Data delayed at least 15 minutes, as of Sep 18 2024 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Immunitybio Inc1.31m-597.65m2.31bn622.00------1,767.96-0.9356-0.93560.0021-1.010.0036--0.492,082.80-162.54-112.76-1,927.61-316.07-----45,701.07-37,700.743.88-2.333.69--159.1767.62-40.00--18.48--
Maravai Lifesciences Holdings Inc278.59m-132.08m2.33bn580.00--5.33--8.37-0.998-0.9982.091.730.15013.076.36428,592.30-8.7412.67-11.3815.4646.7374.79-58.2437.329.28-1.590.41670.00-67.2818.47-154.05--78.56--
Azenta Inc658.62m-156.38m2.40bn3.30k--1.24--3.65-2.82-2.8111.7339.500.24433.083.49188,176.30-5.80-0.5934-6.27-0.672539.7843.08-23.74-2.174.21--0.00--19.731.04-14.15--25.26--
Arrowhead Pharmaceuticals Inc19.65m-538.64m2.49bn525.00--7.52--126.61-4.65-4.650.17012.660.0234----37,424.76-65.18-20.02-73.62-24.65-----2,785.85-61.79---154.930.00---1.0371.68-16.59--162.38--
CG Oncology Inc650.00k-75.84m2.53bn61.00--4.56--3,895.63-1.17-1.170.018.29------10,655.74-------------9,870.92------0.00--6.81---54.83------
Janux Therapeutics Inc15.13m-44.05m2.58bn64.00--3.92--170.56-0.9152-0.91520.308812.610.0293----236,359.40-8.53---8.78-------291.17------0.00---6.14--7.56------
Agios Pharmaceuticals Inc31.31m-364.93m2.60bn383.00--3.93--83.03-6.49-6.490.556811.610.03370.168710.4181,738.91-39.28-29.54-41.94-31.8889.33---1,165.69-3,826.109.71--0.00--88.36-22.25-51.89---32.23--
SpringWorks Therapeutics Inc86.19m-301.06m2.63bn305.00--4.72--30.52-4.44-4.441.257.500.1519----282,577.10-53.07-36.97-57.99-39.4995.27---349.32-2,176.467.77--0.00-------17.19--90.68--
Veracyte Inc399.58m-54.04m2.64bn815.00--2.33--6.60-0.7444-0.74445.3714.760.33368.118.62490,281.00-4.51-6.33-4.77-6.6968.7367.10-13.52-20.994.17--0.00009--21.7631.45-103.51--39.67--
Protagonist Therapeutics Inc319.12m169.95m2.65bn125.0017.034.8815.488.292.642.645.229.210.6825--449.462,849,286.0036.35-35.9039.20-41.36----53.26-332.81----0.00--125.7314.1738.02--4.62--
ACADIA Pharmaceuticals Inc890.53m30.57m2.70bn630.0089.685.2264.183.030.18130.18135.383.121.141.839.601,491,682.003.93-27.505.93-32.7391.7295.623.43-38.351.95--0.00--40.4526.5571.62--79.52--
PTC Therapeutics, Inc.900.45m-479.52m2.70bn988.00------3.00-6.32-6.3211.84-12.750.55342.164.94911,390.70-29.47-26.71-44.23-33.4692.3593.94-53.25-83.802.17-1.161.70--34.2028.78-12.09--32.00--
Celldex Therapeutics, Inc.8.30m-150.22m2.73bn160.00--3.36--329.28-2.74-2.740.148112.280.0145--10.0551,887.50-26.24-29.65-27.27-31.42-----1,809.40-1,747.94----0.00--192.02-6.32-25.91--17.46--
Geron Corp1.37m-219.55m2.74bn141.00--8.92--1,997.61-0.3595-0.35950.00230.51030.0032--0.63679,737.59-50.78-51.32-63.77-64.9063.00---15,990.60-19,949.133.60--0.2139---60.23-25.97-29.76--120.29--
Apogee Therapeutics Inc0.00-118.49m2.96bn91.00--3.71-----2.25-2.250.0013.650.00----0.00-25.44---26.65--------------0.00-------111.10------
Data as of Sep 18 2024. Currency figures normalised to Veracyte Inc's reporting currency: US Dollar USD

Institutional shareholders

59.14%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 20247.35m9.57%
ARK Investment Management LLCas of 30 Jun 20246.81m8.87%
BlackRock Fund Advisorsas of 30 Jun 20246.37m8.29%
Wellington Management Co. LLPas of 30 Jun 20246.28m8.18%
Dimensional Fund Advisors LPas of 30 Jun 20243.29m4.29%
Nikko Asset Management Americas, Inc.as of 30 Jun 20243.18m4.14%
Champlain Investment Partners LLCas of 30 Jun 20243.17m4.12%
Artisan Partners LPas of 30 Jun 20243.06m3.99%
ArrowMark Colorado Holdings LLCas of 30 Jun 20243.00m3.90%
SSgA Funds Management, Inc.as of 30 Jun 20242.91m3.79%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.